Egypt HIV Therapeutics Market Analysis Report [2022-30]

Egypt HIV Therapeutics Market Analysis

$ 3999

The Egypt HIV therapeutics market is expected to reach $53.34 Mn by 2030, up from $38.53 Mn in 2022, with a CAGR of 4.2% from 2022 to 2030. Local Players such as EVA Pharma, FHI 360, and Egypt Pharma dominate the HIV therapeutics market in Egypt. The government policies, funding, and initiatives by UNICEF to manage HIV infections in the country propel the market growth. The HIV therapeutics market in Egypt is divided into four segments: type, product, geography, end user, and distribution channel.

ID: IN10EGPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Dr. Vishwa Modhia

Buy Now

Egypt HIV Therapeutics Market Analysis Summary

The Egypt HIV therapeutics market is expected to reach $53.34 Mn by 2030, up from $38.53 Mn in 2022, with a CAGR of 4.2% from 2022 to 2030.

Egypt is a North African country that borders the Red Sea and the Mediterranean Sea. Libya, the Gaza Strip, and Sudan are among the neighboring countries. In 2020, Egypt's adult HIV/AIDS prevalence was less than 0.1 %, with 24,000 active HIV cases. According to the most recent WHO data published in 2020, the number of HIV/AIDS deaths in Egypt reached 397, accounting for 0.07% of all deaths.

Egypt ranks 127th in the world with an age-adjusted death rate of 0.41 per 100,000 population. Egypt continues to have a low HIV prevalence, with evidence of a concentrated epidemic among injecting drug users and men who have sex with men in Cairo and Alexandria. In 2020, Egypt will spend 4.4 % of its GDP on healthcare.

egypt HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers

Mother and child HIV/AIDS prevention, treatment, care, and support needs have been included in the National Strategic Plan largely owing to UNICEF's technical guidance and advocacy efforts. UNICEF's assistance with anti-retroviral treatment procurement and supply management (ARVs). Every month, approximately 4000 people living with HIV receive high-quality HIV treatment medications, including pregnant women, infants, and adolescents, as well as Egyptians and refugees. These factors may entice new players to enter Egypt's HIV therapeutics market.

Market Restraint

It is extremely difficult to provide prevention services to the most vulnerable populations, primarily because their behaviors are considered crimes under Egyptian law. Treatment dropout is high in the first year of treatment for a variety of personal and structural reasons, including a lack of treatment knowledge and support. These factors may discourage new entrants into Egypt's HIV therapeutics market.

Competitive Landscape

Key Players

FHI 360 (EGY)
EVA Pharma (EGY)
ViiV Healthcare
Bristol Myers Squibb
Merck & Co.
Gilead Sciences
AbbVie
Roche

Recent Notable Updates

December 2022: EVA Pharma collaborates with Egypt's Ministry of Health and UNAIDS to launch an HIV awareness campaign. The Egyptian Ministry of Health and Population's National AIDS Control Program, in collaboration with the Joint United Nations Programme on HIV/AIDS (UNAIDS) and leading pharmaceutical company EVA Pharma, has launched a new campaign to combat HIV discrimination and address societal fears about the disease. In conjunction with World AIDS Day, the "Zay Ay Marad" ("Like Any Disease") campaign was launched. The program aims to coordinate efforts with all parties to combat the disease, reduce infections, and maintain Egypt's status as a low-infection-rate country, all while working to eradicate AIDS in Egypt and meet the 2030 Sustainable Development Goals.

Healthcare Regulations and Reimbursement Policies

The Egyptian Drug Authority (EDA) is the regulatory body in charge of the approval and oversight of medicines, including HIV therapeutics, in Egypt. The EDA is in charge of evaluating and approving applications for marketing authorization for medicines, as well as monitoring and enforcing regulatory compliance. In Egypt, the EDA is a regulatory body that reports to the Ministry of Health and Population. In addition to the EDA, the Ministry of Health and Population has established HIV treatment and prevention guidelines and regulations.

The Egyptian government provides free antiretroviral therapy (ART) for the treatment of HIV to all people living with the virus, including foreign residents. As a result, there is no need for reimbursement for the cost of HIV therapeutics in Egypt because the government provides them free of charge.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.